Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer
Smruti Koppikar, Ana Oaknin, K. Govind Babu, Domenica Lorusso, Sudeep Gupta, Lanxia Wu, Wulyo Rajabto, Kenichi Harano, S.-H. Hong, Rozita Abdul Malik, Heinrik Martin Jude S. Strebel, Ieera Aggarwal, Chyong‐Huey Lai, Thitiya Dejthevaporn, Siriwan Tangjitgamol, Wen‐Fang Cheng, Wen Yee Chay, Doris R. Benavides, Najihah Mohd Hashim, Yong Wha Moon, Mayu Yunokawa, Tricia Dewi Anggraeni, Wen Wei, Giuseppe Curigliano, Amita Maheshwari, Umesh Mahantshetty, Suma Sheshadri, Solange Peters, Takayuki Yoshino, George Pentheroudakis
Abstract
•This article provides the ESMO recommendations for the treatment of endometrial cancer adapted for patients in Asian countries.•The lack of availability of certain tests and treatments in some Asian countries is discussed for few recommendations.•The aim is to encourage evidence-based practices in the management of endometrial cancer in the different regions of Asia. The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer was published in 2022. It was therefore decided, by both the ESMO and the Indian Society of Medical and Paediatric Oncology (ISMPO), to convene a virtual meeting in July 2022 to adapt the ESMO 2022 guidelines to take into account the variations in the management of endometrial cancer in Asia. These guidelines represent the consensus opinion of a panel of Asian experts representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). Voting was based on scientific evidence and was conducted independently of the current treatment practices and treatment access constraints in the different Asian countries, which were discussed when appropriate. The aim of this guideline manuscript is to provide guidance for the optimisation and harmonisation of the management of patients with endometrial cancer across the different regions of Asia, drawing on the evidence provided by Western and Asian trials whilst respecting the variations in clinical presentation, diagnostic practices including molecular profiling and disparities in access to therapeutic options, including drug approvals and reimbursement strategies. The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer was published in 2022. It was therefore decided, by both the ESMO and the Indian Society of Medical and Paediatric Oncology (ISMPO), to convene a virtual meeting in July 2022 to adapt the ESMO 2022 guidelines to take into account the variations in the management of endometrial cancer in Asia. These guidelines represent the consensus opinion of a panel of Asian experts representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). Voting was based on scientific evidence and was conducted independently of the current treatment practices and treatment access constraints in the different Asian countries, which were discussed when appropriate. The aim of this guideline manuscript is to provide guidance for the optimisation and harmonisation of the management of patients with endometrial cancer across the different regions of Asia, drawing on the evidence provided by Western and Asian trials whilst respecting the variations in clinical presentation, diagnostic practices including molecular profiling and disparities in access to therapeutic options, including drug approvals and reimbursement strategies.